Welcome

The Mississippi Society of Oncology was formed in 1991 for the purpose of promoting the highest professional standards of oncology in Mississippi, to study, research and exchange information, experiences and ideas leading to improvement in oncology and promote educational opportunities.

In addition,  the MOS is committed to support the search for more effective treatments of malignant diseases, work with other organizations and societies that have concerns with cancer care, and disseminate information regarding regulatory developments affecting members.

And finally the MOS  acts as a resource for insurers regarding the standard of care in oncology and represents the practice of oncology and hematology in the State of Mississippi.

____________________________________________________________

Click here for the PDF brochure
Click here for registration information

Announcements

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.  Click here for more.

-------------------------------------------------------------------------------------------------------

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card

Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.   Click here for more.

------------------------------------------------------------------------------------------------------

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain

Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease

Click here for more.


COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories

COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Click here for More.

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials

Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for More.

ASTRO releases updated radiation oncology safety guide

In conjunction with Patient Safety Awareness Week, the American Society for Radiation Oncology (ASTRO)published an update today to its framework for safe and effective radiation therapy treatment. The comprehensive reference guide, Safety is No Accident: A Framework for Quality Radiation Oncology and Care, is available for download.


  • No upcoming events

News

The cumulative production of 400,000 UDENYCA® pre-filled syringes is a significant milestone, as it represents approximately one-third of the annual utilization of pegfilgrastim in the United States.

Click here for more.

Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule. 

The CMS fact sheet is available here.  In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.

Click here for more.

Click here for more




┬ę 2008-2019  Mississippi Oncology Society.
All rights reserved | Phone: 601-909-3036

Powered by Wild Apricot Membership Software